Clinical Trials Browser

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Early Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Non-squamous NSCLC

Carcinoma, Non-Small-Cell Lung

Breast Cancer Invasive

Advanced Breast Cancer

HER2-positive Breast Cancer

Breast Cancer Female

Locally Advanced Breast Cancer

Non Small Cell Lung

HER2-positive Breast Cancer

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Advanced Digestive System Tumor

Breast Neoplasms

Clinical Trials

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

NUMER

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

ctDNA in HER2+ EBC Neoadjuvant Treatment

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

TAYLOR

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

PYRAMID-1

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

CORINNE-PI

CORIN-PYRA

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NeoATP

ATP

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

FASCINATE-N

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

HER2-DM-NACT

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

CCGLC-018

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer